Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141897 | 0.69 | OR51E2 (0.32) | — | |
| SCHEMBL171558 | 0.69 | NNMT (0.35) | NNMTUHRF1 | |
| SCHEMBL558013 | 0.67 | — | — | |
| SCHEMBL159386 | 0.67 | CDK5 (0.33) | — | |
| SCHEMBL2073119 | 0.67 | UHRF1 (0.42) | NNMTUHRF1 | |
| SCHEMBL5761232 | 0.67 | NNMT (0.39) | NNMTUHRF1 | |
| SCHEMBL29799324 | 0.67 | NNMT (0.50) | NNMTUHRF1 | |
| SCHEMBL1553765 | 0.67 | NNMT (0.50) | NNMTUHRF1 | |
| SCHEMBL4148663 | 0.65 | CDK5 (0.32) | — | |
| SCHEMBL18592832 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | claimed |
| US-20120245139-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-27 | — | — | US | claimed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | claimed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | claimed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | claimed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | claimed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | claimed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | claimed |
| CN-118252829-A | CRF receptor antagonists and methods of use | 纽罗克里生物科学有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024091542-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091541-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4330232-A1 | GPR52 MODULATORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-5026851-A | Antineoplastic agents | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4845216-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0215063-A4 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES. | UNIV PRINCETON (US) | 1987-11-23 | — | — | EP | disclosed |
| US-4684653-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0215063-A1 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES. | UNIV PRINCETON (US) | 1987-03-25 | — | — | EP | disclosed |
| WO-1986005181-A1 | PYRIDO AD2,3-d BDPYRIMIDIN DERIVATIVES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1986-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | NNMT 3450/4885UHRF1 538/4885 |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | NNMT 1734/4885UHRF1 4082/4885 |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | NNMT 3768/4885UHRF1 679/4885 |
| US-20120245139-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | NNMT 3450/4885UHRF1 538/4885 |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | NNMT 2435/4885UHRF1 4440/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | NNMT 1504/4885UHRF1 3531/4885 |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NNMT 280/4885UHRF1 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.